High-Level Expression of microRNA-21 in Peripheral Blood Mononuclear Cells Is a Diagnostic and Prognostic Marker in Prostate Cancer

Genetic Testing and Molecular Biomarkers

Volumn 19, Issue 9, 2015, Pages 469-475

  Huang, Wei ^a   Kang, Xin Li ^b   Cen, Son ^b   Wang, Yang ^b   Chen, Xiang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HAINAN PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 21; MICRORNA; MIRN21 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FLUORESCENCE ANALYSIS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION; BIOSYNTHESIS; BLOOD; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MOLECULAR DIAGNOSIS; MONONUCLEAR CELL; PROCEDURES; PROGNOSIS; PROSTATE TUMOR; RISK FACTOR;

ADULT; AGED; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MICRORNAS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PROGNOSIS; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS;

EID: 84941648706     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2015.0088     Document Type: Article

References (30)

1. Achyut BR, Bader DA, Robles AI, et al. (2013) Inflammationmediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-beta signaling. PLoS Genet 9:e1003251.
2. Ahmed A, Ali S, Sarkar FH (2014) Advances in androgen receptor targeted therapy for prostate cancer. J Cell Physiol 229:271-276.
3. Amankwah EK, Anegbe E, Park H, et al. (2013) miR-21, miR-221 and miR-222 expression and prostate cancer recurrence among obese and non-obese cases. Asian J Androl 15:226-230.
4. Brase JC, Johannes M, Schlomm T, et al. (2011) Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128:608-616.
5. Chun FK (2008) Editorial comment on: 11C-choline-positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 54:400-401.
6. Coppola V, Musumeci M, Patrizii M, et al. (2013) BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelialmesenchymal transition. Oncogene 32:1843-1853.
7. Frankel LB, Christoffersen NR, Jacobsen A, et al. (2008) Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 283:1026-1033.
8. Fujita S, Ito T, Mizutani T, et al. (2008) miR-21 Gene expression triggered by AP-1 is sustained through a doublenegative feedback mechanism. J Mol Biol 378:492-504.
9. Haimov-Kochman R, Fisher SJ, Winn VD (2006) Modification of the standard Trizol-based technique improves the integrity of RNA isolated from RNase-rich placental tissue. Clin Chem 52:159-160.
10. Heitzer E, Auer M, Hoffmann EM, et al. (2013) Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer 133:346-356.
11. Li L, Zhang Y, Guo BB, et al. (2014) Oncogenic induction of cellular high CpG methylation by Epstein-Barr virus in malignant epithelial cells. Chin J Cancer 33:604-608.
12. Li T, Li D, Sha J, et al. (2009) MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 383: 280-285.
13. Li T, Li RS, Li YH, et al. (2012) miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer. J Urol 187:1466-1472.
14. Lim AC, Attard G (2013) Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer. Curr Drug Targets 14: 408-419.
15. M PN (2014) World Medical Association publishes the Revised Declaration of Helsinki. Natl Med J India 27:56.
16. Martens-Uzunova ES, Jalava SE, Dits NF, et al. (2012) Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 31:978-991.
17. Melbo-Jorgensen C, Ness N, Andersen S, et al. (2014) Stromal expression of MiR-21 predicts biochemical failure in prostate cancer patients with Gleason score 6. PLoS One 9:e113039.
18. Morimura R, Komatsu S, Ichikawa D, et al. (2011) Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer 105:1733-1740.
19. Oesterling JE, Suman VJ, Zincke H, et al. (1993) PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors. Urol Clin North Am 20:687-693.
20. Reis ST, Pontes-Junior J, Antunes AA, et al. (2012) miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer. BMC Urol 12:14.
21. Ribas J, Ni X, Haffner M, et al. (2009) miR-21: an androgen receptor-regulated microRNA that promotes hormonedependent and hormone-independent prostate cancer growth. Cancer Res 69:7165-7169.
22. Rumsby M, Schmitt J, Sharrard M, et al. (2011) Human prostate cell lines from normal and tumourigenic epithelia differ in the pattern and control of choline lipid headgroups released into the medium on stimulation of protein kinase C. Br J Cancer 104:673-684.
23. Schweizer MT, Huang P, Kattan MW, et al. (2013) Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials. Cancer 119:3610-3618.
24. Shen J, Hruby GW, McKiernan JM, et al. (2012) Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 72:1469-1477.
25. Shinjo K, Okamoto Y, An B, et al. (2012) Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. Carcinogenesis 33:1277-1285.
26. Sita-Lumsden A, Dart DA, Waxman J, et al. (2013) Circulating microRNAs as potential new biomarkers for prostate cancer. Br J Cancer 108:1925-1930.
27. Suardi N, Gandaglia G, Gallina A, et al. (2015) Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol 67:299-309.
28. Triantafyllou M, Studer UE, Birkhauser FD, et al. (2013) Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer. Eur J Cancer 49:616-624.
29. Wang B, Zhang Q (2012) The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol 138:1659-1666.
30. Zheng Q, Peskoe SB, Ribas J, et al. (2014) Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy. Prostate 74:1655-1662.